Indian pharma leaders' push for faster approvals resurfaces as government plans 1,000 trial centres
Resurfacing a February 2026 call, executives from Sun Pharma, Cipla, Dr Reddy's and Lupin urged simpler regulation, faster clinical-trial approvals and stronger domestic trial infrastructure to accelerate drug innovation.
The development
Indian pharmaceutical leaders called for regulatory reform as the government plans to certify 1,000 clinical trial centres. Sun Pharma, Cipla, Dr Reddy’s and Lupin executives said faster approvals, stronger trials infrastructure and domestic acceptance are needed to accelerate innovation.
The numbers
- Phase-I
- 1,000
- 1972
- multi-billion-dollar
Why it matters to operators and investors
Pharma deal teams may find growing opportunities in clinical-research partnerships, trial-site networks and assets whose value improves with faster Indian approval pathways.
What to watch next
- Publication of the 1,000-centre implementation plan, certification criteria, funding structure and state-level allocation.
- CDSCO or health-ministry changes to clinical-trial review timelines, single-window submissions, ethics-committee rules or import permissions.
- Reported median approval times and number of new trial approvals, especially for Phase II/III studies and biosimilars.
- Accreditation growth in tier-2 and tier-3 city hospitals, along with investigator and CRO hiring trends.
- Any trial-safety, data-integrity or patient-consent controversy that could trigger regulatory tightening.
- R&D guidance from Sun Pharma, Cipla, Dr Reddy's and Lupin indicating higher domestic clinical-development spending.
- Prioritise partnerships with certified Indian trial sites, hospital networks and CROs in high-recruitment therapeutic areas.
- Build regulatory-affairs and clinical-operations capacity to submit trial applications rapidly if approval timelines shorten.
- Shift a larger share of biosimilar, complex generic and specialty-drug development studies to India where patient access and investigator capability are strongest.
- Invest in electronic data capture, pharmacovigilance, trial-monitoring and participant-consent systems to meet stricter quality expectations.
- For pharmacy and healthcare retailers, evaluate opportunities to support patient recruitment, adherence services, diagnostics and post-marketing evidence generation through compliant partnerships.
The counter-case
The announcement is aspirational rather than operational: adding 1,000 trial centres could create fragmented, underused capacity if investigator quality, patient recruitment, ethics oversight, data integrity and site reimbursement do not improve in parallel. Faster approvals may also face justified resistance if regulators prioritize safety and protocol scrutiny after past concerns around clinical-trial governance. Industry calls for simplification may primarily seek lower timelines and compliance burden, not reforms that demonstrably improve innovation outcomes.